{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T23:15:15Z","timestamp":1777418115091,"version":"3.51.4"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,6,27]],"date-time":"2025-06-27T00:00:00Z","timestamp":1750982400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,6,27]],"date-time":"2025-06-27T00:00:00Z","timestamp":1750982400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P01CA233432"],"award-info":[{"award-number":["P01CA233432"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P01CA233432"],"award-info":[{"award-number":["P01CA233432"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P01CA233432"],"award-info":[{"award-number":["P01CA233432"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P01CA233432"],"award-info":[{"award-number":["P01CA233432"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P01CA233432"],"award-info":[{"award-number":["P01CA233432"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P01CA233432"],"award-info":[{"award-number":["P01CA233432"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P01CA233432"],"award-info":[{"award-number":["P01CA233432"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P01CA233432"],"award-info":[{"award-number":["P01CA233432"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P01CA233432"],"award-info":[{"award-number":["P01CA233432"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P01CA233432"],"award-info":[{"award-number":["P01CA233432"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P01CA233432"],"award-info":[{"award-number":["P01CA233432"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P01CA233432"],"award-info":[{"award-number":["P01CA233432"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1007\/s10549-025-07760-0","type":"journal-article","created":{"date-parts":[[2025,6,27]],"date-time":"2025-06-27T02:02:31Z","timestamp":1750989751000},"page":"81-92","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Trastuzumab therapy and new-onset hypertension in adolescents and young adults with breast cancer"],"prefix":"10.1007","volume":"213","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1644-0313","authenticated-orcid":false,"given":"Renata","family":"Abrah\u00e3o","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kathryn J.","family":"Ruddy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cecile A.","family":"Laurent","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jessica","family":"Chubak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric C.","family":"Haupt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ann M.","family":"Brunson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erin E.","family":"Hahn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chun R.","family":"Chao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisa M.","family":"Moy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ted","family":"Wun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lawrence H.","family":"Kushi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Theresa H. M.","family":"Keegan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Candice A. M.","family":"Sauder","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,6,27]]},"reference":[{"issue":"15","key":"7760_CR1","doi-asserted-by":"publisher","first-page":"1647","DOI":"10.1200\/JCO.21.01736","volume":"40","author":"H Greenlee","year":"2022","unstructured":"Greenlee H, Iribarren C, Rana JS, Cheng R, Nguyen-Huynh M, Rillamas-Sun E, Shi Z et al (2022) Risk of cardiovascular disease in women with and without breast cancer: the pathways heart study. J Clin Oncol 40(15):1647\u20131658","journal-title":"J Clin Oncol"},{"key":"7760_CR2","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.ijcard.2019.01.082","volume":"281","author":"G Tini","year":"2019","unstructured":"Tini G, Sarocchi M, Tocci G, Arboscello E, Ghigliotti G, Novo G, Brunelli C et al (2019) Arterial hypertension in cancer: the elephant in the room. Int J Cardiol 281:133\u2013139","journal-title":"Int J Cardiol"},{"issue":"2","key":"7760_CR3","doi-asserted-by":"publisher","first-page":"e2254669","DOI":"10.1001\/jamanetworkopen.2022.54669","volume":"6","author":"CM Larsen","year":"2023","unstructured":"Larsen CM, Garcia Arango M, Dasari H, Arciniegas Calle M, Adjei E, Rico Mesa J, Scott CG et al (2023) Association of anthracycline with heart failure in patients treated for breast cancer or lymphoma, 1985\u20132010. JAMA Netw Open 6(2):e2254669","journal-title":"JAMA Netw Open"},{"issue":"13","key":"7760_CR4","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1177\/2047487320915342","volume":"28","author":"CC Nwabuo","year":"2021","unstructured":"Nwabuo CC, Appiah D, Moreira HT, Vasconcellos HD, Yano Y, Reis JP, Shah RV et al (2021) Long-term cumulative blood pressure in young adults and incident heart failure, coronary heart disease, stroke, and cardiovascular disease: the CARDIA study. Eur J Prev Cardiol 28(13):1445\u20131451","journal-title":"Eur J Prev Cardiol"},{"issue":"25","key":"7760_CR5","doi-asserted-by":"publisher","first-page":"3808","DOI":"10.1200\/JCO.2006.10.4976","volume":"25","author":"MC Pinder","year":"2007","unstructured":"Pinder MC, Duan Z, Goodwin JS, Hortobagyi GN, Giordano SH (2007) Congestive heart failure in older women treated with adjuvant anthracycline chemotherapy for breast cancer. J Clin Oncol 25(25):3808\u20133815","journal-title":"J Clin Oncol"},{"issue":"36","key":"7760_CR6","doi-asserted-by":"publisher","first-page":"2768","DOI":"10.1093\/eurheartj\/ehw211","volume":"37","author":"JL Zamorano","year":"2016","unstructured":"Zamorano JL, Lancellotti P, Rodriguez Mu\u00f1oz D, Aboyans V, Asteggiano R, Galderisi M, Habib G et al (2016) 2016 ESC position paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC committee for practice guidelines: the task force for cancer treatments and cardiovascular toxicity of the European society of cardiology (ESC). Eur Heart J 37(36):2768\u20132801","journal-title":"Eur Heart J"},{"issue":"4","key":"7760_CR7","first-page":"Cd006243","volume":"2012","author":"L Moja","year":"2012","unstructured":"Moja L, Tagliabue L, Balduzzi S, Parmelli E, Pistotti V, Guarneri V, D\u2019Amico R (2012) Trastuzumab containing regimens for early breast cancer. Cochrane Database Syst Rev 2012(4):Cd006243","journal-title":"Cochrane Database Syst Rev"},{"issue":"10075","key":"7760_CR8","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1016\/S0140-6736(16)32616-2","volume":"389","author":"D Cameron","year":"2017","unstructured":"Cameron D, Piccart-Gebhart MJ, Gelber RD, Procter M, Goldhirsch A, de Azambuja E, Castro G Jr et al (2017) 11 years\u2019 follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial. Lancet (London, England) 389(10075):1195\u20131205","journal-title":"Lancet (London, England)"},{"issue":"6","key":"7760_CR9","first-page":"006242","volume":"2014","author":"S Balduzzi","year":"2014","unstructured":"Balduzzi S, Mantarro S, Guarneri V, Tagliabue L, Pistotti V, Moja L, D\u2019Amico R (2014) Trastuzumab-containing regimens for metastatic breast cancer. Cochrane Database Syst Rev 2014(6):006242","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"7760_CR10","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2203690","volume":"387","author":"S Modi","year":"2022","unstructured":"Modi S, Jacot W, Yamashita T, Sohn J, Vidal M, Tokunaga E, Tsurutani J et al (2022) Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer. N Engl J Med 387(1):9\u201320","journal-title":"N Engl J Med"},{"issue":"12","key":"7760_CR11","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1056\/NEJMoa2115022","volume":"386","author":"J Cort\u00e9s","year":"2022","unstructured":"Cort\u00e9s J, Kim SB, Chung WP, Im SA, Park YH, Hegg R, Kim MH et al (2022) Trastuzumab deruxtecan versus trastuzumab emtansine for breast cancer. N Engl J Med 386(12):1143\u20131154","journal-title":"N Engl J Med"},{"issue":"23","key":"7760_CR12","doi-asserted-by":"publisher","first-page":"3525","DOI":"10.1200\/JCO.2007.11.0106","volume":"25","author":"ML Telli","year":"2007","unstructured":"Telli ML, Hunt SA, Carlson RW, Guardino AE (2007) Trastuzumab-related cardiotoxicity: calling into question the concept of reversibility. J Clin Oncol 25(23):3525\u20133533","journal-title":"J Clin Oncol"},{"issue":"9","key":"7760_CR13","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1016\/j.mayocp.2014.05.013","volume":"89","author":"J Herrmann","year":"2014","unstructured":"Herrmann J, Lerman A, Sandhu NP, Villarraga HR, Mulvagh SL, Kohli M (2014) Evaluation and management of patients with heart disease and cancer: cardio-oncology. Mayo Clin Proc 89(9):1287\u20131306","journal-title":"Mayo Clin Proc"},{"issue":"2","key":"7760_CR14","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1007\/s11523-009-0112-2","volume":"4","author":"E de Azambuja","year":"2009","unstructured":"de Azambuja E, Bedard PL, Suter T, Piccart-Gebhart M (2009) Cardiac toxicity with anti-HER-2 therapies: what have we learned so far? Target Oncol 4(2):77\u201388","journal-title":"Target Oncol"},{"issue":"3","key":"7760_CR15","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1002\/cncr.34505","volume":"129","author":"AM Berkman","year":"2023","unstructured":"Berkman AM, Andersen CR, Roth ME, Gilchrist SC (2023) Cardiovascular disease in adolescent and young adult cancer survivors: impact of sociodemographic and modifiable risk factors. Cancer 129(3):450\u2013460","journal-title":"Cancer"},{"issue":"25","key":"7760_CR16","doi-asserted-by":"publisher","first-page":"2206","DOI":"10.1200\/JCO.19.00882","volume":"37","author":"SA Hurvitz","year":"2019","unstructured":"Hurvitz SA, Martin M, Jung KH, Huang CS, Harbeck N, Valero V, Stroyakovskiy D et al (2019) Neoadjuvant trastuzumab emtansine and pertuzumab in human epidermal growth factor receptor 2-positive breast cancer: three-year outcomes from the phase III KRISTINE study. J Clin Oncol 37(25):2206\u20132216","journal-title":"J Clin Oncol"},{"issue":"7","key":"7760_CR17","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1056\/NEJMoa1814017","volume":"380","author":"G von Minckwitz","year":"2019","unstructured":"von Minckwitz G, Huang CS, Mano MS, Loibl S, Mamounas EP, Untch M, Wolmark N et al (2019) Trastuzumab emtansine for residual invasive HER2-positive breast cancer. N Engl J Med 380(7):617\u2013628","journal-title":"N Engl J Med"},{"issue":"22","key":"7760_CR18","doi-asserted-by":"publisher","first-page":"3974","DOI":"10.1002\/cncr.32392","volume":"125","author":"EA Perez","year":"2019","unstructured":"Perez EA, Barrios C, Eiermann W, Toi M, Im YH, Conte P, Martin M et al (2019) Trastuzumab emtansine with or without pertuzumab versus trastuzumab with taxane for human epidermal growth factor receptor 2-positive advanced breast cancer: final results from MARIANNE. Cancer 125(22):3974\u20133984","journal-title":"Cancer"},{"issue":"12","key":"7760_CR19","doi-asserted-by":"publisher","first-page":"1734","DOI":"10.1016\/j.mayocp.2014.08.011","volume":"89","author":"J Herrmann","year":"2014","unstructured":"Herrmann J, Herrmann SM, Haddad TC (2014) New-onset heart failure in association with severe hypertension during trastuzumab therapy. Mayo Clin Proc 89(12):1734\u20131739","journal-title":"Mayo Clin Proc"},{"issue":"20","key":"7760_CR20","doi-asserted-by":"publisher","first-page":"2441","DOI":"10.1001\/jama.291.20.2441","volume":"291","author":"JF Piccirillo","year":"2004","unstructured":"Piccirillo JF, Tierney RM, Costas I, Grove L, Spitznagel EL Jr (2004) Prognostic importance of comorbidity in a hospital-based cancer registry. JAMA 291(20):2441\u20132447","journal-title":"JAMA"},{"issue":"3","key":"7760_CR21","doi-asserted-by":"publisher","first-page":"e46","DOI":"10.1161\/HYP.0000000000000224","volume":"80","author":"JB Cohen","year":"2023","unstructured":"Cohen JB, Brown NJ, Brown SA, Dent S, van Dorst DCH, Herrmann SM, Lang NN et al (2023) Cancer therapy-related hypertension: a scientific statement from the American heart association. Hypertension 80(3):e46\u2013e57","journal-title":"Hypertension"},{"issue":"27","key":"7760_CR22","doi-asserted-by":"publisher","first-page":"3161","DOI":"10.1200\/JCO.20.00722","volume":"38","author":"C Chao","year":"2020","unstructured":"Chao C, Bhatia S, Xu L, Cannavale KL, Wong FL, Huang PS, Cooper R et al (2020) Chronic comorbidities among survivors of adolescent and young adult cancer. J Clin Oncol 38(27):3161\u20133174","journal-title":"J Clin Oncol"},{"key":"7760_CR23","unstructured":"Kaiser Permanente Washington Health Research Institute (2024) VOICE study: valuing opinions and insight from cancer experiences. https:\/\/www.kpwashingtonresearch.org\/voicestudy. Accessed 10 Jan 2025"},{"issue":"2","key":"7760_CR24","doi-asserted-by":"publisher","first-page":"87","DOI":"10.7812\/TPP\/22.172","volume":"27","author":"AC Davis","year":"2023","unstructured":"Davis AC, Voelkel JL, Remmers CL, Adams JL, McGlynn EA (2023) Comparing kaiser permanente members to the general population: implications for generalizability of research. Perm J 27(2):87\u201398","journal-title":"Perm J"},{"key":"7760_CR25","doi-asserted-by":"publisher","first-page":"26","DOI":"10.3389\/fcvm.2020.00026","volume":"7","author":"D Cardinale","year":"2020","unstructured":"Cardinale D, Iacopo F, Cipolla CM (2020) Cardiotoxicity of anthracyclines. Front Cardiovasc Med 7:26","journal-title":"Front Cardiovasc Med"},{"issue":"4","key":"7760_CR26","doi-asserted-by":"publisher","first-page":"214","DOI":"10.2174\/157340311799960645","volume":"7","author":"M Volkova","year":"2011","unstructured":"Volkova M, Russell R 3rd (2011) Anthracycline cardiotoxicity: prevalence, pathogenesis and treatment. Curr Cardiol Rev 7(4):214\u2013220","journal-title":"Curr Cardiol Rev"},{"issue":"2","key":"7760_CR27","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1097\/JHQ.0000000000000332","volume":"44","author":"C Levitz","year":"2022","unstructured":"Levitz C, Jones M, Nudelman J, Cox M, Camacho D, Wielunski A, Rothman M et al (2022) Reducing cardiovascular risk for patients with diabetes: an evidence-based, population health management program. J Healthc Qual 44(2):103\u2013112","journal-title":"J Healthc Qual"},{"key":"7760_CR28","unstructured":"Lin G, So Y, Johnston G. Analyzing survival data with competing risks using SAS\u00ae software. SAS Global Forum 2012 Conference. SAS Institute Inc, Cary"},{"issue":"1","key":"7760_CR29","first-page":"22","volume":"9","author":"H Eaton","year":"2023","unstructured":"Eaton H, Timm KN (2023) Mechanisms of trastuzumab induced cardiotoxicity \u2013 is exercise a potential treatment? Cardio-Oncol 9(1):22","journal-title":"Cardio-Oncol"},{"issue":"35","key":"7760_CR30","doi-asserted-by":"publisher","first-page":"3942","DOI":"10.1200\/JCO.2017.74.1165","volume":"35","author":"PA Ganz","year":"2017","unstructured":"Ganz PA, Romond EH, Cecchini RS, Rastogi P, Geyer CE Jr, Swain SM, Jeong JH et al (2017) Long-term follow-up of cardiac function and quality of life for patients in NSABP protocol B-31\/NRG oncology: a randomized trial comparing the safety and efficacy of doxorubicin and cyclophosphamide (AC) followed by paclitaxel with AC followed by paclitaxel and trastuzumab in patients with node-positive breast cancer with tumors overexpressing human epidermal growth factor receptor 2. J Clin Oncol 35(35):3942\u20133948","journal-title":"J Clin Oncol"},{"issue":"6","key":"7760_CR31","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1200\/JCO.2015.61.8413","volume":"34","author":"PP Advani","year":"2016","unstructured":"Advani PP, Ballman KV, Dockter TJ, Colon-Otero G, Perez EA (2016) Long-term cardiac safety analysis of NCCTG N9831 (alliance) adjuvant trastuzumab trial. J Clin Oncol 34(6):581\u2013587","journal-title":"J Clin Oncol"},{"issue":"9","key":"7760_CR32","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1038\/nrcardio.2015.65","volume":"12","author":"MS Ewer","year":"2015","unstructured":"Ewer MS, Ewer SM (2015) Cardiotoxicity of anticancer treatments. Nat Rev Cardiol 12(9):547\u2013558","journal-title":"Nat Rev Cardiol"},{"key":"7760_CR33","unstructured":"National Comprehensive Cancer Network (NCCN) (2024) Clinical practice guidelines in oncology for breast cancer. Version 1. https:\/\/www.nccn.org\/guidelines\/category_1. Accessed 10 Feb 2024"},{"key":"7760_CR34","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1007\/s10549-023-06997-x","volume":"201","author":"E Rillamas-Sun","year":"2023","unstructured":"Rillamas-Sun E, Kwan ML, Carlos C, Cheng R, Neugebauer R, Rana JS, Nguyen-Huynh M et al (2023) Development of cardiometabolic risk factors following endocrine therapy in women with breast cancer. Breast Cancer Res Treat 201:117","journal-title":"Breast Cancer Res Treat"},{"issue":"2","key":"7760_CR35","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1007\/s10549-017-4447-6","volume":"166","author":"A Blaes","year":"2017","unstructured":"Blaes A, Beckwith H, Florea N, Hebbel R, Solovey A, Potter D, Yee D et al (2017) Vascular function in breast cancer survivors on aromatase inhibitors: a pilot study. Breast Cancer Res Treat 166(2):541\u2013547","journal-title":"Breast Cancer Res Treat"},{"issue":"11","key":"7760_CR36","doi-asserted-by":"publisher","first-page":"860","DOI":"10.7326\/0003-4819-115-11-860","volume":"115","author":"RR Love","year":"1991","unstructured":"Love RR, Wiebe DA, Newcomb PA, Cameron L, Leventhal H, Jordan VC, Feyzi J et al (1991) Effects of tamoxifen on cardiovascular risk factors in postmenopausal women. Ann Intern Med 115(11):860\u2013864","journal-title":"Ann Intern Med"},{"issue":"11","key":"7760_CR37","doi-asserted-by":"publisher","first-page":"3133","DOI":"10.3390\/jcm11113133","volume":"11","author":"K Boszkiewicz","year":"2022","unstructured":"Boszkiewicz K, Piwowar A, Petryszyn P (2022) Aromatase inhibitors and risk of metabolic and cardiovascular adverse effects in breast cancer patients-a systematic review and meta-analysis. J Clin Med 11(11):3133","journal-title":"J Clin Med"},{"issue":"8","key":"7760_CR38","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1016\/S0895-7061(02)02951-5","volume":"15","author":"GS Stergiou","year":"2002","unstructured":"Stergiou GS, Zourbaki AS, Efstathiou SP, Stathopoulos GP, Keramopoulos AD, Mountokalakis TD (2002) Effect of estrogen receptor modulator tamoxifen on blood pressure, plasma renin activity, and renal sodium excretion. Am J Hypertens 15(8):739\u2013742","journal-title":"Am J Hypertens"},{"issue":"1","key":"7760_CR39","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.clbc.2016.07.003","volume":"17","author":"J Foglietta","year":"2017","unstructured":"Foglietta J, Inno A, de Iuliis F, Sini V, Duranti S, Turazza M, Tarantini L et al (2017) Cardiotoxicity of aromatase inhibitors in breast cancer patients. Clin Breast Cancer 17(1):11\u201317","journal-title":"Clin Breast Cancer"},{"issue":"17","key":"7760_CR40","doi-asserted-by":"publisher","first-page":"1774","DOI":"10.1001\/jama.2018.13551","volume":"320","author":"Y Yano","year":"2018","unstructured":"Yano Y, Reis JP, Colangelo LA, Shimbo D, Viera AJ, Allen NB, Gidding SS et al (2018) Association of blood pressure classification in young adults using the 2017 American college of cardiology\/American heart association blood pressure guideline with cardiovascular events later in life. JAMA 320(17):1774\u20131782","journal-title":"JAMA"},{"issue":"6","key":"7760_CR41","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1007\/s40615-020-00741-7","volume":"7","author":"MS Williams","year":"2020","unstructured":"Williams MS, Beech BM, Griffith DM Jr, Thorpe RJ (2020) The association between hypertension and race\/ethnicity among breast cancer survivors. J Racial Ethn Health Disparities 7(6):1172\u20131177","journal-title":"J Racial Ethn Health Disparities"},{"issue":"15_suppl","key":"7760_CR42","doi-asserted-by":"publisher","first-page":"e24092","DOI":"10.1200\/JCO.2020.38.15_suppl.e24092","volume":"38","author":"MF Chen","year":"2020","unstructured":"Chen MF, Manson DK, Yuan A, Crew KD (2020) Trastuzumab-induced cardiotoxicity and hypertension among racially and ethnically diverse patients with HER2-positive early-stage breast cancer. J Clin Oncol 38(15_suppl):e24092","journal-title":"J Clin Oncol"},{"issue":"3","key":"7760_CR43","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1007\/s40615-018-00557-6","volume":"6","author":"MY Jung","year":"2019","unstructured":"Jung MY, Lee S, Thomas SB, Juon HS (2019) Hypertension prevalence, treatment, and related behaviors among Asian Americans: an examination by method of measurement and disaggregated subgroups. J Racial Ethn Health Disparities 6(3):584\u2013593","journal-title":"J Racial Ethn Health Disparities"},{"key":"7760_CR44","first-page":"1","volume":"364","author":"Y Ostchega","year":"2020","unstructured":"Ostchega Y, Fryar CD, Nwankwo T, Nguyen DT (2020) Hypertension prevalence among adults aged 18 and over: United States, 2017\u20132018. NCHS Data Brief 364:1\u20138","journal-title":"NCHS Data Brief"},{"issue":"2","key":"7760_CR45","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1080\/00325481.2016.1147927","volume":"128","author":"T De Venecia","year":"2016","unstructured":"De Venecia T, Lu M, Figueredo VM (2016) Hypertension in young adults. Postgrad Med 128(2):201\u2013207","journal-title":"Postgrad Med"},{"issue":"6","key":"7760_CR46","doi-asserted-by":"publisher","first-page":"1971","DOI":"10.1161\/HYPERTENSIONAHA.120.15761","volume":"76","author":"S van Oort","year":"2020","unstructured":"van Oort S, Beulens JWJ, van Ballegooijen AJ, Grobbee DE, Larsson SC (2020) Association of cardiovascular risk factors and lifestyle behaviors with hypertension: a mendelian randomization study. Hypertension 76(6):1971\u20131979","journal-title":"Hypertension"},{"issue":"4","key":"7760_CR47","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1007\/s00467-020-04579-3","volume":"36","author":"M Litwin","year":"2021","unstructured":"Litwin M, Ku\u0142aga Z (2021) Obesity, metabolic syndrome, and primary hypertension. Pediatr Nephrol 36(4):825\u2013837","journal-title":"Pediatr Nephrol"},{"issue":"1","key":"7760_CR48","first-page":"43","volume":"66","author":"CD Runowicz","year":"2016","unstructured":"Runowicz CD, Leach CR, Henry NL, Henry KS, Mackey HT, Cowens-Alvarado RL, Cannady RS et al (2016) American cancer society\/American society of clinical oncology breast cancer survivorship care guideline. CA Cancer J Clin 66(1):43\u201373","journal-title":"CA Cancer J Clin"},{"issue":"4","key":"7760_CR49","first-page":"355","volume":"13","author":"A Denegri","year":"2016","unstructured":"Denegri A, Moccetti T, Moccetti M, Spallarossa P, Brunelli C, Ameri P (2016) Cardiac toxicity of trastuzumab in elderly patients with breast cancer. J Geriatr Cardiol 13(4):355\u2013363","journal-title":"J Geriatr Cardiol"},{"issue":"1","key":"7760_CR50","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.113.000472","volume":"3","author":"G Ezaz","year":"2014","unstructured":"Ezaz G, Long JB, Gross CP, Chen J (2014) Risk prediction model for heart failure and cardiomyopathy after adjuvant trastuzumab therapy for breast cancer. J Am Heart Assoc 3(1):e000472","journal-title":"J Am Heart Assoc"},{"issue":"31","key":"7760_CR51","doi-asserted-by":"publisher","first-page":"7820","DOI":"10.1200\/JCO.2005.13.300","volume":"23","author":"MS Ewer","year":"2005","unstructured":"Ewer MS, Vooletich MT, Durand J-B, Woods ML, Davis JR, Valero V, Lenihan DJ (2005) Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment. J Clin Oncol 23(31):7820\u20137826","journal-title":"J Clin Oncol"},{"key":"7760_CR52","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1186\/s12885-015-1696-9","volume":"15","author":"SL Gomez","year":"2015","unstructured":"Gomez SL, Shariff-Marco S, Von Behren J, Kwan ML, Kroenke CH, Keegan TH, Reynolds P et al (2015) Representativeness of breast cancer cases in an integrated health care delivery system. BMC Cancer 15:688","journal-title":"BMC Cancer"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-025-07760-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10549-025-07760-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-025-07760-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T01:05:32Z","timestamp":1757207132000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10549-025-07760-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,27]]},"references-count":52,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["7760"],"URL":"https:\/\/doi.org\/10.1007\/s10549-025-07760-0","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"value":"0167-6806","type":"print"},{"value":"1573-7217","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,27]]},"assertion":[{"value":"23 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}